Trexquant Investment LP Acquires Shares of 12,776 Heron Therapeutics Inc (HRTX)
Trexquant Investment LP bought a new position in Heron Therapeutics Inc (NASDAQ:HRTX) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 12,776 shares of the biotechnology company’s stock, valued at approximately $206,000.
A number of other hedge funds have also recently added to or reduced their stakes in the business. Chartwell Investment Partners LLC purchased a new stake in Heron Therapeutics in the 3rd quarter worth approximately $2,340,000. C WorldWide Group Holding A S purchased a new stake in Heron Therapeutics in the 3rd quarter worth approximately $1,615,000. Asymmetry Capital Management L.P. purchased a new stake in Heron Therapeutics in the 3rd quarter worth approximately $1,017,000. Fisher Asset Management LLC purchased a new stake in Heron Therapeutics in the 3rd quarter worth approximately $1,621,000. Finally, Mesirow Financial Investment Management Inc. purchased a new stake in Heron Therapeutics in the 2nd quarter worth approximately $509,000.
Several analysts have commented on HRTX shares. Noble Financial reaffirmed a “buy” rating and issued a $24.00 target price on shares of Heron Therapeutics in a research note on Friday, October 6th. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Heron Therapeutics in a research note on Monday, September 25th. Zacks Investment Research raised shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 8th. Cowen reaffirmed a “buy” rating and issued a $40.00 target price on shares of Heron Therapeutics in a research note on Monday, November 6th. Finally, Oppenheimer began coverage on shares of Heron Therapeutics in a research note on Monday, October 30th. They issued a “buy” rating and a $27.00 target price for the company. Two investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $28.73.
Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.77) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.87) by $0.10. Heron Therapeutics had a negative net margin of 488.40% and a negative return on equity of 307.76%. The company had revenue of $8.57 million during the quarter, compared to analysts’ expectations of $8.12 million. sell-side analysts forecast that Heron Therapeutics Inc will post -3.43 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Trexquant Investment LP Acquires Shares of 12,776 Heron Therapeutics Inc (HRTX)” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://www.thecerbatgem.com/2017/12/10/trexquant-investment-lp-acquires-shares-of-12776-heron-therapeutics-inc-hrtx.html.
Heron Therapeutics Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Stock Ratings for Heron Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc and related stocks with our FREE daily email newsletter.